Edition:
United Kingdom

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

81.83USD
9:00pm BST
Change (% chg)

$-0.75 (-0.91%)
Prev Close
$82.58
Open
$82.12
Day's High
$82.81
Day's Low
$81.37
Volume
1,322,097
Avg. Vol
1,874,167
52-wk High
$139.70
52-wk Low
$74.14

Latest Key Developments (Source: Significant Developments)

Oncomed Provides Update On Navicixizumab Partnership
Thursday, 20 Sep 2018 

Sept 20 (Reuters) - OncoMed Pharmaceuticals Inc ::ONCOMED PROVIDES UPDATE ON NAVICIXIZUMAB PARTNERSHIP.ONCOMED PHARMACEUTICALS - CELGENE NOTIFIED CO IT DECIDED NOT TO EXERCISE ITS OPTION TO LICENSE CO'S BISPECIFIC ANTIBODY NAVICIXIZUMAB.ONCOMED PHARMACEUTICALS INC - ONCOMED AND CELGENE ARE WORKING TO FORMALIZE TERMINATION OF COLLABORATION AGREEMENT WITH RESPECT TO NAVICIXIZUMAB.ONCOMED PHARMACEUTICALS - CELGENE CONTINUES TO RETAIN ITS OPTIONS TO LICENSE ONCOMED'S ETIGILIMAB UNDER COLLABORATION.ONCOMED PHARMACEUTICALS INC - EXPECTS TO RETAIN WORLDWIDE RIGHTS TO NAVICIXIZUMAB.ONCOMED PHARMACEUTICALS INC - ONCOMED EXPECTS TO RETAIN WORLDWIDE RIGHTS TO NAVICIXIZUMAB.  Full Article

Celgene Says Otezla Showed Meaningful Improvements Psoriasis Patients
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Celgene Corp ::OTEZLA® (APREMILAST) SHOWED MEANINGFUL IMPROVEMENTS IN CLINICAL AND QUALITY-OF-LIFE MEASURES OF PSORIASIS BEYOND THOSE CAPTURED BY ASSESSING SKIN ALONE.CELGENE - PATIENTS WITH MODERATE-SEVERE PLAQUE PSORIASIS SHOWED MEANINGFUL IMPROVEMENTS IN SKIN, ITCH, OTHERS AMONG PASI 75 NON-RESPONDERS TREATED WITH OTEZLA.CELGENE CORP - SEPARATE POST HOC SUB-ANALYSIS OF DATA FROM PHASE 3 ESTEEM 1 & 2 &PHASE 4 UNVEIL TRIALS SHOWED IMPROVEMENT WITH OTEZLA VERSUS PLACEBO.  Full Article

Agios Pharmaceuticals - Co, Celgene Agreed To Terminate Collaboration, License Deal
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS PHARMACEUTICALS INC - ON SEPT 4, CO, CELGENE AGREED TO TERMINATE COLLABORATION AND LICENSE DEAL DATED APRIL 27, 2015 BETWEEN CO AND CELGENE.AGIOS PHARMA- FOR SPECIFIED PERIOD CELGENE SHALL BE PROHIBITED FROM DEVELOPING, COMMERCIALIZING PRODUCT THAT INHIBITS ISOCITRATE DEHYDROGENASE 1.AGIOS - ON SEPT 4, CO, CELGENE ALSO AGREED TO TERMINATE LICENSE AGREEMENT DATED APRIL 27, 2015 BETWEEN CO'S UNIT AND CELGENE INTERNATIONAL II SARL.AGIOS PHARMACEUTICALS INC - PROHIBITED PRODUCTS APPLY FOR INHIBITS ISOCITRATE DEHYDROGENASE 1 AT SPECIFIED LEVELS OF BINDING FOR ANY INDICATION.AGIOS PHARMACEUTICALS INC - COMPANY SHALL BE PROHIBITED FROM DEVELOPING, MANUFACTURING OR COMMERCIALIZING AG-881 IN HEMATOLOGIC INDICATIONS.AGIOS PHARMACEUTICALS - FROM & AFTER AG-881 AGREEMENT TERMINATION DATE, CO TO OBTAIN SOLE GLOBAL RIGHTS TO AG-881 - SEC FILING.AGIOS PHARMACEUTICALS - NO PARTY TO HAVE FINANCIAL OBLIGATION TO OTHER PARTIES, INCLUDING MILESTONES, ROYALTIES, OTHER PAYMENTS AFTER TERMINATION DATE.  Full Article

• BLUEBIRD BIO SAYS CELGENE AMENDED PHASE 2 STUDY PROTOCOL
Thursday, 12 Jul 2018 

July 12 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO - CO, CELGENE CONTINUE TO ANTICIPATE A POTENTIAL APPROVAL OF BB2121 PRODUCT CANDIDATE IN RELAPSED & REFRACTORY MULTIPLE MYELOMA IN 2020.BLUEBIRD BIO SAYS CELGENE HAS AMENDED STUDY PROTOCOL FOR KARMMA STUDY, AN ONGOING PHASE 2 STUDY OF BB2121 PRODUCT CANDIDATE - SEC FILING.BLUEBIRD BIO - DOSE RANGE FOR KARMMA STUDY WILL BE 150 TO 450 X 10(6)CAR+ T CELLS AND ENROLLMENT WILL INCREASE TO UP TO 140 PATIENTS.BLUEBIRD BIO INC - IN ADDITION, CELGENE HAS AMENDED STUDY PROTOCOL FOR CRB-401, AN ONGOING PHASE I STUDY OF BB2121 PRODUCT CANDIDATE.BLUEBIRD BIO INC - ENROLLMENT FOR CRB-401 STUDY WILL BE INCREASED BY UP TO 20 PATIENTS, WITH A DOSE RANGE OF 150 TO 450 X 10(6)CAR+ T CELLS.  Full Article

Celgene Corp Says Phase III Impassion130 Study Met Co-Primary Endpoint Of Progression-Free Survival
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Celgene Corp ::ANTI-PD-L1 IMMUNOTHERAPY PLUS ABRAXANE® SIGNIFICANTLY REDUCED THE RISK OF DISEASE WORSENING OR DEATH IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER IN PHASE III IMPASSION130 STUDY.CELGENE CORP - PHASE III IMPASSION130 STUDY, WHICH WAS SPONSORED BY ROCHE, MET ITS CO-PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL.CELGENE - OVERALL SURVIVAL IS ENCOURAGING IN PD-L1 POSITIVE POPULATION AT INTERIM ANALYSIS, FOLLOW UP WILL CONTINUE UNTIL NEXT PLANNED ANALYSIS.CELGENE CORP - SAFETY IN TECENTRIQ PLUS ABRAXANE ARM APPEARED CONSISTENT WITH KNOWN SAFETY PROFILES OF INDIVIDUAL MEDICINES.CELGENE CORP - NO NEW SAFETY SIGNALS WERE IDENTIFIED WITH IN TECENTRIQ PLUS ABRAXANE COMBINATION.CELGENE CORP - DATA DEMONSTRATE POTENTIAL ROLE OF ABRAXANE AS PREFERRED CHEMOTHERAPY PARTNER FOR IMMUNOTHERAPY COMBINATIONS.  Full Article

Celgene And Acceleron says Luspatercept Achieved main goals in study
Monday, 9 Jul 2018 

July 10 (Reuters) - Celgene Corp ::CELGENE AND ACCELERON ANNOUNCE LUSPATERCEPT ACHIEVED PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN PHASE III ‘BELIEVE’ STUDY IN ADULTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA.CELGENE CORP - RESULTS SHOWED A SIGNIFICANT REDUCTION IN TRANSFUSION BURDEN COMPARED TO PLACEBO.CELGENE CORP - REGULATORY SUBMISSIONS PLANNED IN UNITED STATES AND EUROPE IN FIRST HALF OF 2019.CELGENE CORP - SAFETY PROFILE GENERALLY CONSISTENT WITH PREVIOUSLY REPORTED DATA.CELGENE CORP - ADVERSE EVENTS OBSERVED IN STUDY WERE GENERALLY CONSISTENT WITH PREVIOUSLY REPORTED DATA.CELGENE CORP - DATA FROM BELIEVE AND MEDALIST WILL BE SUBMITTED TO A FUTURE MEDICAL MEETING IN 2018.  Full Article

Celgene Says Co Settled Litigations With Accord Healthcare Relating To Patents For Revlimid (Lenalidomide)
Thursday, 5 Jul 2018 

July 5 (Reuters) - Celgene Corp ::CELGENE CORPORATION - SETTLED LITIGATIONS WITH ACCORD HEALTHCARE (ACCORD) RELATING TO PATENTS FOR REVLIMID (LENALIDOMIDE).CELGENE- IN SETTLEMENT, ACCORD TO VACATE CHALLENGES TO CO'S PATENTS;CO GRANTED ACCORD ABILITY TO MARKET GENERIC LENALIDOMIDE PRODUCT ON CONDITIONS.CELGENE- GRANTED ACCORD MARKETING ABILITY OF GENERIC LENALIDOMIDE ON CONDITIONS PRIOR TO EXPIRY OF CO'S PATENT, SPC RIGHTS IN U.K. STARTING JAN 18, 2022.CELGENE- ALSO GRANTED ACCORD MARKETING ABILITY OF GENERIC ON CONDITIONS IN VARIOUS OTHER EUROPEAN COUNTRIES WHERE CO'S SPC IN FORCE FROM FEB 18, 2022.  Full Article

Celgene And Acceleron Announce Luspatercept Achieved Primary And Key Secondary Endpoints In Study
Thursday, 28 Jun 2018 

June 28 (Reuters) - Celgene Corp ::CELGENE AND ACCELERON ANNOUNCE LUSPATERCEPT ACHIEVED PRIMARY AND KEY SECONDARY ENDPOINTS IN PHASE III ‘MEDALIST’ STUDY IN PATIENTS WITH LOW-TO-INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES.CELGENE CORP - RESULTS SHOWED SIGNIFICANT IMPROVEMENT IN RED BLOOD CELL TRANSFUSION INDEPENDENCE COMPARED TO PLACEBO.CELGENE CORP - SAFETY PROFILE GENERALLY CONSISTENT WITH PREVIOUSLY PUBLISHED DATA.CELGENE CORP - REGULATORY SUBMISSIONS PLANNED IN UNITED STATES AND EUROPE IN FIRST HALF OF 2019.CELGENE - IN ADDITION TO ACHIEVING PRIMARY ENDPOINT OF STUDY, LUSPATERCEPT ALSO MET KEY SECONDARY ENDPOINT.CELGENE CORP - ADVERSE EVENTS OBSERVED IN STUDY WERE GENERALLY CONSISTENT WITH PREVIOUSLY PUBLISHED DATA.  Full Article

Skyhawk Therapeutics Announces Strategic Collaboration With Celgene
Tuesday, 26 Jun 2018 

June 26 (Reuters) - Celgene Corp ::SKYHAWK THERAPEUTICS ANNOUNCES STRATEGIC COLLABORATION WITH CELGENE TO DISCOVER AND DEVELOP NOVEL MRNA SPLICING MODIFIERS USING SKYHAWK'S STAR* TECHNOLOGY PLATFORM.SKYHAWK THERAPEUTICS SAYS SKYHAWK AND CELGENE ENTER INTO A FIVE-YEAR STRATEGIC COLLABORATION.SKYHAWK THERAPEUTICS SAYS COLLABORATION INCLUDES UPFRONT PAYMENT OF $60 MILLION, AND POTENTIAL FUTURE LICENSE FEES, MILESTONE PAYMENTS, AND ROYALTIES.SKYHAWK- GRANTS CELGENE EXCLUSIVE OPTION TO IN-LICENSE WORLDWIDE INTELLECTUAL PROPERTY RIGHTS RELATED TO THERAPEUTIC CANDIDATES FOR UP TO 5 PROGRAMS.SKYHAWK THERAPEUTICS SAYS ALSO ANNOUNCED CLOSING OF A NEW EQUITY INVESTMENT ROUND WITH NEW INVESTMENTS BY GREATPOINT VENTURES AND CELGENE.  Full Article

Celgene Says Entered Into Agreement To Implement Accelerated Share Repurchase Program
Thursday, 31 May 2018 

May 31 (Reuters) - Celgene Corp ::CELGENE - ENTERED INTO AGREEMENT TO IMPLEMENT AN ACCELERATED SHARE REPURCHASE PROGRAM.CELGENE CORP - ASR PROGRAM IS EXPECTED TO BE COMPLETED ON OR BEFORE AUGUST 31, 2018.CELGENE - ASR AGREEMENT PROVIDES, AMONG OTHER THINGS, THAT CO PAID CITIBANK $2.0 BILLION, INITIALLY RECEIVED 17,987,922 SHARES OF COMMON STOCK.CELGENE - ASR PROGRAM WAS FUNDED WITH A COMBINATION OF CASH ON HAND & PROCEEDS OF COMMERCIAL PAPER BORROWINGS CO EXPECTS TO REPAY BY END OF 2018.  Full Article

UPDATE 1-Rare manufacturing glitch raises concern over CAR-T therapies -study

CHICAGO, Oct 1 A single leukemia cell inadvertently got mixed in with a batch of a patient's immune cells that were being manufactured into a CAR-T cell therapy and it acquired resistance to the treatment with deadly results, University of Pennsylvania researchers reported on Monday.